Blueprint Medicines Corporation clinical trials
Acquired by Sanofi, Jul 18, 2025 · source ↗
The registry lists 32 studies whose lead sponsor is Blueprint Medicines Corporation. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 12, 2026.
- 32studies on the registry
- 6open to participants now
- 1phase 3 study under way
- 2reach primary completion within a year
Before and after it joined Sanofi
- First submitted before Blueprint Medicines Corporation became part of Sanofi
- 27
- First submitted after Blueprint Medicines Corporation became part of Sanofi
- 5
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Blueprint Medicines Corporation’s studies test, most open studies first — 6 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
- Avapritinib1 in phase 31 open · 9
- elenestinib1 in phase 31 open · 3
- 0 open · 3
- 0 open · 2
- 0 open · 1
- 0 open · 1
Coming up
2 of Blueprint Medicines Corporation’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 1DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- 1JJun
- JJul
- AAug
- SSep
- OOct
- NNov
All 2
- Dec 2026Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)BLU-808 · NCT06931405
- Jun 2027(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisAvapritinib · NCT03731260
Add all 2 to your calendar (.ics) → With an account.
All 32 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 522
- 23
- 24
- 25
- 326
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Blueprint Medicines Corporation32 studies
Something wrong with this grouping? Tell us on the Sanofi page.
Studies
Recruiting first, then most recently updated. Showing 32 of 32. All Sanofi studies →
- Avapritinib Rollover StudyRecruitingNCT06748001Phase 4
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisRecruitingNCT04910685Phase 2/3
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in GermanyRecruitingNCT07255638
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted after Blueprint Medicines Corporation became part of Sanofi
- Screening Study for KIT D816V Mutated Mast Cell Disease in Select PopulationsRecruitingNCT07143669
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted after Blueprint Medicines Corporation became part of Sanofi
- A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsRecruitingNCT07629960Phase 1/2
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted after Blueprint Medicines Corporation became part of Sanofi
- An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)RecruitingNCT07264959
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted after Blueprint Medicines Corporation became part of Sanofi
- (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisCompletedNCT03580655Phase 2
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisActive, not recruitingNCT03731260Phase 2
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- Study of BLU-808 in Allergic RhinoconjunctivitisCompletedNCT06922448Phase 2
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)Active, not recruitingNCT06931405Phase 2
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- A Study of Elenestinib in Healthy Adult Female ParticipantsCompletedNCT07388511Phase 1
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted after Blueprint Medicines Corporation became part of Sanofi
- A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA SignalingCompletedNCT04773782Phase 1/2
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- (VELA) Study of BLU-222 in Advanced Solid TumorsTerminatedNCT05252416Phase 1
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- Study of BLU-808 in Healthy Adult ParticipantsCompletedNCT06948032Phase 1
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic MalignanciesTerminatedNCT05609942Phase 1
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsTerminatedNCT05241873Phase 1
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCTerminatedNCT04862780Phase 1
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- A Drug-drug Interaction Study of Avapritinib and MidazolamCompletedNCT04908176Phase 1
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- Study for Patients Previously Treated in Avapritinib Clinical TrialsCompletedNCT04825574Phase 4
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- Expanded Access Program for AvapritinibNo longer availableNCT04714086
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaCompletedNCT02508467Phase 1
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLCTerminatedNCT05153408Phase 1
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- (PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell ActivationCompletedNCT04811365
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesCompletedNCT02561988Phase 1
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Phase 3
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid TumorsCompletedNCT02508532Phase 1
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSMCompletedNCT04695431
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTCApproved for marketingNCT04204928
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLCStatus unknownNCT04697446
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- Mast Cell Connect: A Registry for Patients With MastocytosisCompletedNCT02620254
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GISTApproved for marketingNCT03862885
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi
- Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy AdultsCompletedNCT03858075Phase 1
Sponsor listed in the registry: Blueprint Medicines Corporation · First submitted before Blueprint Medicines Corporation became part of Sanofi